Articles tagged "Monitoring"

2022 American Transplant Congress
The Effect of Baseline Blood Pressure on Early Graft Function in Deceased Donor Kidney Transplantation
B. Jun Bae¹, C. Oh¹, H. Ahn²
¹Department of surgery, Ajou University Medical School, Suwon, Korea, Republic of, ²Department of Anesthesiology and Pain medicine, Ajou University Medical School, Suwon, Korea, Republic of
*Purpose: The adequate perfusion pressure to the graft is essential for proper graft function in kidney transplantation, especially in deceased donor kidney transplantation. Therefore, the…
2022 American Transplant Congress
Measurement of Physical Activity and Frailty in the Early Post-Operative Period After Kidney Transplant-Single-Center Prospective Pilot Study Using Fitbit Watch
T. Shamaa, L. Allenspach, O. Shamaa, S. Shimada, C. Crombez, O. Hage-Hassan, T. Kitajima, S. Yeddula, I. Bajjoka, L. Malinzak, J. Denny, D. Kim, M. Abouljoud, S. Nagai
Henry Ford Transplant Institute, Detroit, MI
*Purpose: Physical activity monitors (PAMs) allow patients to track multiple health parameters. PAM’s may be helpful to assess a patient’s physical recovery after a Kidney…
2022 American Transplant Congress
Utility of Donor Derived Cell-Free DNA in Liver Transplantation
A. Zarrinpar, D. Lewis, C. Warren, S. Duarte
Surgery, University of Florida, Gainesville, FL
*Purpose: As a non-invasive measure of allograft injury, quantifying the fraction of donor-derived cell-free DNA (dd-cfDNA) has proven to be useful technique in kidney transplantation.…
2022 American Transplant Congress
Early Experience with OmniGraf® Biomarker Surveillance in Kidney Transplant Patients in the First-Year Post-Transplant and Beyond
V. Paramasivam¹, W. Ally², B. Sivakumar³, B. Greco¹, M. Germain¹
¹Baystate Medical Center, Springfield, MA, ²Eurofins Transplant Genomics, Framingham, MA, ³Dartmouth College, Hanover, NH
*Purpose: Non-invasive rejection biomarkers continue to evolve with recent data supporting the use of combined gene expression and donor derived cell-free DNA (dd-cfDNA) in kidney…
2022 American Transplant Congress
Clinical Stratification of Pediatric Liver Transplant Recipients 4-5 Years Post-Transplant: 1^St Step Towards Personalized Management
W. Dixon¹, E. R. Perito¹, M. Tavakol¹, J. Bucuvalas², S. Feng¹
¹University of California, San Francisco, San Francisco, CA, ²Mount Sinai Kravis Children's Hospital and Recanati/Miller Transplantation Institute, Mount Sinai Health System, New York, NY
*Purpose: Recent surveillance biopsy studies strongly associate high normal ALT (>35U/L) with inflammatory histopathology and low normal ALT (15yrs (n=13; p=0.0006), chronic rejection (CR) diagnosis…
2022 American Transplant Congress
A Novel, High Throughput Droplet Digital PCR-Based Indel Quantification Method for the Detection of Circulating Donor-Derived Cell-Free DNA After Kidney Transplantation
J. G. Verhoeven¹, K. Boer¹, A. M. Peeters¹, M. C. Clahsen-van Groningen², J. I. Roodnat¹, J. van de Wetering¹, D. Nieboer³, D. A. Bost⁴, C. C. Baan¹, D. A. Hesselink¹
¹Department of Internal Medicine, Erasmus MC Transplant Institute, Rotterdam, Netherlands, ²Department of Pathology, University Medical Center Rotterdam, Rotterdam, Netherlands, ³Department of Public Health, University Medical Center Rotterdam, Rotterdam, Netherlands, ⁴JETA Molecular, Utrecht, Netherlands
*Purpose: Donor-derived cell-free DNA (ddcfDNA) is a promising minimally invasive biomarker for acute rejection (AR) in kidney transplant recipients. To assess the diagnostic value of…
2021 American Transplant Congress
Remote Monitoring Using Mobile Phlebotomy and Donor-derived Cell-free DNA in Kidney Transplant Recipients During the Covid-19 Pandemic
N. Ali¹, J. Miles², V. Tatapudi¹, R. Montgomery¹
¹NYU Langone, New York, NY, ²Medical Science Liason, CareDx, Brisbane, CA
*Purpose: The rapid shift to telemedicine and remote monitoring of kidney transplant recipients (KTRs) during COVID-19 aimed to mitigate exposure risk for this vulnerable population.…
2021 American Transplant Congress
Single Center Experience Comparing Two Clinically Available Donor Derived Cell Free DNA Tests
S. Bunnapradist¹, S. Lee², P. Homkrailas³, G. Danovitch³
¹UCLA, Los Angeles, CA, ²Pharmacy, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: Donor derived cell-free DNA (dd cf-DNA), this new technology allows for non-invasive monitoring of graft function. Two most commonly used assays are Prospera (Natera®,…
2021 American Transplant Congress
A Reliable Non Invasive Alternative to Surveillance Renal Allograft Biopsy
R. Jain, S. Thaduri, V. Kumar, C. Kew, B. Julian, G. Towns, S. Ong, F. Ahmed, S. Mehta, G. Agarwal
Transplant Nephrology, University of Alabama Birmingham, Birmingham, AL
*Purpose:Surveillance Renal Allograft Biopsy (SAVB) is the standard of care to identify subclinical immunological injury(SCI). However fewer than 25% of transplant centers in the US…
2021 American Transplant Congress
Comparison of Donor-derived Cell Free Dna Between Recipients with First Solitary Allograft and Regrafts
S. Paluri¹, S. Muthusamy¹, M. Shinbashi¹, G. Gupta¹, B. Dale², Z. Kashi³, P. Halloran⁴, D. Kumar¹
¹Virginia Commonwealth University, Richmond, VA, ²CareDx, Brisbane, CA, ³Kashi Clinical Laboratories, Portland, OR, ⁴ATAGC, Edmonton, AB, Canada
*Purpose: Donor derived-cell free DNA (dd-cfDNA) is a biomarker of immunological injury. Multiple studies have validated its utility in recipients of first solitary kidney transplants…